{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:48:38Z","timestamp":1782719318913,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14651-7","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:43:02Z","timestamp":1777887782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regional features in the treatment of Parkinson\u2019s disease in the Baltic States compared to Germany"],"prefix":"10.1186","volume":"26","author":[{"given":"Paula","family":"Abola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligita","family":"Smeltere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta Kaladyte","family":"Lokominiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Straeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlheinz","family":"Reinfrank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Sikk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pille","family":"Taba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"1","key":"14651_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1","volume":"1","author":"A Kouli","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan WL. Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. Parkinson\u2019s Disease: Pathogenesis Clin Aspects. 2018;1(1):3\u201326. https:\/\/doi.org\/10.15586\/codonpublications.parkinsonsdisease.2018.ch1.","journal-title":"Parkinson\u2019s Disease: Pathogenesis Clin Aspects"},{"issue":"2","key":"14651_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5152\/npa.2016.12758","volume":"54","author":"GOKCALE GUR","year":"2017","unstructured":"Gur Gokcale, Selvitop VE, Babacan Yildiz G R. Motor and non-motor symptoms in Parkinson\u2019s Disease: effects on quality of life. Noro Psikiyatri Arsivi. 2017;54(2):143\u20138. https:\/\/doi.org\/10.5152\/npa.2016.12758.","journal-title":"Noro Psikiyatri Arsivi"},{"key":"14651_CR3","unstructured":"Rommel A, Deuschl G, Dodel R et al. Die Parkinsonkrankheit \u2013 Pr\u00e4valenz, trends und regionale verteilung in Deutschland. Eine Auswertung auf Basis von GKV-Routinedaten. Edocrkide. Published online 2025. http:\/\/edoc.rki.de\/176904\/12463."},{"issue":"1\u20132","key":"14651_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000499756","volume":"53","author":"L Kadastik-Eerme","year":"2019","unstructured":"Kadastik-Eerme L, Taba N, Asser T, Taba P. Incidence and mortality of Parkinson\u2019s disease in Estonia. Neuroepidemiology. 2019;53(1\u20132):63\u201372. https:\/\/doi.org\/10.1159\/000499756.","journal-title":"Neuroepidemiology"},{"issue":"3","key":"14651_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/ane.12948","volume":"138","author":"L Kadastik-Eerme","year":"2018","unstructured":"Kadastik-Eerme L, Taba N, Asser T, Taba P. The increasing prevalence of Parkinson\u2019s disease in Estonia. Acta Neurol Scand. 2018;138(3):251\u20138. https:\/\/doi.org\/10.1111\/ane.12948.","journal-title":"Acta Neurol Scand"},{"key":"14651_CR6","unstructured":"Higienos institutas. Visuomen\u0117s sveikatos steb\u0117senos informacin\u0117 sistema. Sveikstat.hi.lt. Published 2024. https:\/\/sveikstat.hi.lt\/chart-summary-ctry.aspx?top_uid=204_loc=ctry&sel_rep_panel=1=eng."},{"key":"14651_CR7","doi-asserted-by":"publisher","unstructured":"G\u00fcnter H\u00f6glinger, B\u00e4hr M, Becktepe J, et al. Diagnosis and treatment of Parkinson\u00b4s disease (guideline of the German Society for Neurology). Neurol Res Pract. 2024;6(1). https:\/\/doi.org\/10.1186\/s42466-024-00325-4.","DOI":"10.1186\/s42466-024-00325-4"},{"issue":"7","key":"14651_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, et al. European academy of neurology\/movement disorder society-European section guideline on the treatment of Parkinson\u2019s disease: I. invasive therapies. Mov Disord. 2022;37(7):1360\u201374. https:\/\/doi.org\/10.1002\/mds.29066.","journal-title":"Mov Disord"},{"issue":"1","key":"14651_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ene.12022","volume":"20","author":"A Berardelli","year":"2012","unstructured":"Berardelli A, Wenning GK, Antonini A, et al. EFNS\/MDS-ES recommendations for the diagnosis of Parkinson\u2019s disease. Eur J Neurol. 2012;20(1):16\u201334. https:\/\/doi.org\/10.1111\/ene.12022.","journal-title":"Eur J Neurol"},{"issue":"9","key":"14651_CR10","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1111\/ene.15386","volume":"29","author":"D G\u00fcnther","year":"2022","unstructured":"G\u00fcnther D, Antonini A, Costa J, et al. European academy of neurology\/movement disorder society - European section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies. Eur J Neurol. 2022;29(9):2580\u201395. https:\/\/doi.org\/10.1111\/ene.15386.","journal-title":"Eur J Neurol"},{"issue":"11","key":"14651_CR11","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3390\/biomedicines12112426","volume":"12","author":"MG Maggio","year":"2024","unstructured":"Maggio MG, Bonanno M, Manuli A, et al. Advances in the neuro-rehabilitation of Parkinson\u2019s disease: Insights from a personalized multidisciplinary innovative pathway. Biomedicines. 2024;12(11):2426. https:\/\/doi.org\/10.3390\/biomedicines12112426.","journal-title":"Biomedicines"},{"key":"14651_CR12","unstructured":"Nacion\u0101lais vesel\u012bbas dienests. Parkinsona slim\u012bbas un Parkinsona-plus sindromu kl\u012bnisk\u0101s vadl\u012bnijas. Vmnvd.gov.lv. Published 2018. https:\/\/www.vmnvd.gov.lv\/lv\/parkinsona-slimibas-un-parkinsona-plus-sindromu-kliniskas-vadlinijas."},{"key":"14651_CR13","unstructured":"Parkinsono Ligos Profilaktikos Diagnostikos, GYDYMO, Medicinin\u0116s Reabilitacijos IR. Slaugos Metodika. sam.lrv.lt. https:\/\/sam.lrv.lt\/public\/canonical\/1728885168\/26126\/Parkinsono%20liga_galutinis.pdf."},{"key":"14651_CR14","doi-asserted-by":"publisher","unstructured":"Pirto\u0161ek Z. Breaking barriers in Parkinson\u2019s care: the multidisciplinary team approach. J Neural Transm. 2024;131(11). https:\/\/doi.org\/10.1007\/s00702-024-02843-6.","DOI":"10.1007\/s00702-024-02843-6"},{"key":"14651_CR15","unstructured":"National Center for Biotechnology Information. Health care in Germany: The German health care system. Nih gov Published Dec 18, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK298834\/."},{"key":"14651_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.vhri.2017.08.006","volume":"13","author":"J Silins","year":"2017","unstructured":"Silins J, Szkultecka-D\u0119bek M. Drug Policy in Latvia. Value Health Reg Issues. 2017;13:73\u20138. https:\/\/doi.org\/10.1016\/j.vhri.2017.08.006.","journal-title":"Value Health Reg Issues"},{"key":"14651_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2017.10.001","volume":"16","author":"K M\u00e4gi","year":"2018","unstructured":"M\u00e4gi K, Lepaste M, Szkultecka-D\u0119bek M. Drug policy in Estonia. Value Health Reg Issues. 2018;16:1\u20134. https:\/\/doi.org\/10.1016\/j.vhri.2017.10.001.","journal-title":"Value Health Reg Issues"},{"key":"14651_CR18","unstructured":"World Health Organization (WHO). Medicines reimbursement policies in Europe. 2018. https:\/\/iris.who.int\/bitstream\/handle\/10665\/342220\/9789289053365-eng.pdf?sequence=1&isAllowed=y."},{"key":"14651_CR19","doi-asserted-by":"publisher","unstructured":"Medlinskiene K, Tomlinson J, Marques I, Richardson S, Stirling K, Petty D. Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review. BMC Health Serv Res. 2021;21(1). https:\/\/doi.org\/10.1186\/s12913-021-07196-4.","DOI":"10.1186\/s12913-021-07196-4"},{"issue":"2","key":"14651_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.14802\/jmd.23172","volume":"17","author":"K Smilowska","year":"2024","unstructured":"Smilowska K, Pietrzykowski T, Chaudhuri KR, Bloem BR, van Wamelen DJ. Accessibility of device-aided therapies for persons with Parkinson\u2019s disease in Poland. J Mov Disorders. 2024;17(2):208\u201312. https:\/\/doi.org\/10.14802\/jmd.23172.","journal-title":"J Mov Disorders"},{"issue":"4","key":"14651_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s00103-017-2516-y","volume":"60","author":"O Mittag","year":"2017","unstructured":"Mittag O, Welti F. Medizinische rehabilitation im europ\u00e4ischen Vergleich und Auswirkungen des europ\u00e4ischen Rechts auf die deutsche Rehabilitation. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2017;60(4):378\u201385. https:\/\/doi.org\/10.1007\/s00103-017-2516-y.","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"},{"key":"14651_CR22","unstructured":"Gemeinsamer Bundesausschuss. Gemeinsamer Bundesausschuss. www.g-ba.de. https:\/\/www.g-ba.de\/english\/."},{"key":"14651_CR23","unstructured":"Rote Liste. Rote Liste. Rote-liste.de. Published 2025. https:\/\/www.rote-liste.de. Accessed 20 Mar 2025."},{"key":"14651_CR24","unstructured":"Estonian Health Insurance Fund. Estonian Health Insurance Fund. www.tervisekassa.ee. https:\/\/www.tervisekassa.ee\/en."},{"key":"14651_CR25","unstructured":"National Health Insurance Fund Lithuania. National Health Insurance Fund. https:\/\/ligoniukasa.lrv.lt\/en\/."},{"key":"14651_CR26","unstructured":"Nacion\u0101lais. vesel\u012bbas dienests. Nacion\u0101lais vesel\u012bbas dienests. Vmnvd.gov.lv. Published 2022. https:\/\/www.vmnvd.gov.lv\/en. Accessed 20 Mar 2025."},{"key":"14651_CR27","unstructured":"European Academy of Neurology. Guideline Reference Center. ean.org. Published 2025. https:\/\/www.ean.org\/research\/ean-guidelines\/guideline-reference-center."},{"key":"14651_CR28","unstructured":"Latvijas Neirode\u0123enerat\u012bvo slim\u012bbu asoci\u0101cija. Parkinsona Slim\u012bbas Un Parkinsona-plus Sindromu Kl\u012bnisk\u0101s Vadl\u012bnijas Latvijas Neirode\u0123enerat\u012bvo Slim\u012bbu Asoci\u0101cija R\u012aGA 2018. https:\/\/www.spkc.gov.lv\/lv\/registretas-2018gada\/5a816843a5bbc1.pdf."},{"key":"14651_CR29","unstructured":"Grosser J, Greiner W. Sustainability and resilience in the German health system. 2021. https:\/\/www3.weforum.org\/docs\/WEF_PHSSR_Germany_Report.pdf."},{"key":"14651_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-319-51020-0_10","volume":"1","author":"S Klein","year":"2017","unstructured":"Klein S, Schellhammer S. Medication infrastructure development in Germany. Computers Health Care. Published online Jan 2017;1:151\u201370. https:\/\/doi.org\/10.1007\/978-3-319-51020-0_10.","journal-title":"Published online January"},{"key":"14651_CR31","unstructured":"VASPVT. Valstybin\u0117 akreditavimo sveikatos prie\u017ei\u016bros veiklai tarnyba prie Sveikatos apsaugos ministerijos. Vaspvt.gov.lt. Published 2025. https:\/\/licencijavimas.vaspvt.gov.lt\/license\/publicspecialistindex."},{"key":"14651_CR32","unstructured":"Z\u0101\u013cu valsts a\u0123ent\u016bra. Mazina administrat\u012bvo slogu z\u0101\u013cu apg\u0101d\u0113, uzlabojot z\u0101\u013cu pieejam\u012bbu; bezrecep\u0161u medikamentus var\u0113s ieg\u0101d\u0101ties tie\u0161saistes iepirk\u0161an\u0101s platform\u0101s | Z\u0101\u013cu valsts a\u0123ent\u016bra. Zva.gov.lv. Published 2025. https:\/\/www.zva.gov.lv\/lv\/jaunumi-un-publikacijas\/jaunumi\/mazina-administrativo-slogu-zalu-apgade-uzlabojot-zalu-pieejamibu-bezrecepsu-medikamentus-vares."},{"key":"14651_CR33","unstructured":"European Commission. State of Health in the EU Latvia Country Health Profile 2021 the Country Health Profile Series. https:\/\/health.ec.europa.eu\/system\/files\/2021-12\/2021_chp_lv_english.pdf."},{"key":"14651_CR34","unstructured":"National Institute of Health. Advanced therapies: deep brain stimulation and levodopa\u2013carbidopa intestinal gel. https:\/\/www.ncbi.nlm.nih.gov. Published July 1, 2017. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535858\/."},{"key":"14651_CR35","doi-asserted-by":"publisher","unstructured":"Pedrosa DJ, Florin Gandor, Jost WH, Arlt C, Koray Onuk, Timmermann L. Characterization of advanced Parkinson\u2019s disease in Germany: results of the non-interventional OBSERVE-PD study. Neurol Res Pract. 2022;4(1). https:\/\/doi.org\/10.1186\/s42466-022-00176-x.","DOI":"10.1186\/s42466-022-00176-x"},{"issue":"6","key":"14651_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00115-020-00890-4","volume":"91","author":"S Stangl","year":"2020","unstructured":"Stangl S, Haas K, Eggers C, Reese JP, Lars T\u00f6nges, Volkmann J. Versorgung von Parkinson-Patienten in Deutschland. Nervenarzt. 2020;91(6):493\u2013502. https:\/\/doi.org\/10.1007\/s00115-020-00890-4.","journal-title":"Nervenarzt"},{"key":"14651_CR37","doi-asserted-by":"publisher","unstructured":"Henriksen T, Katzenschlager R, Roongroj Bhidayasiri, Staines H, Lockhart D, Lees AJ. Practical use of apomorphine infusion in Parkinson\u2019s disease: lessons from the TOLEDO study and clinical experience. J Neural Transm. Published online September 1, 2023. https:\/\/doi.org\/10.1007\/s00702-023-02686-7.","DOI":"10.1007\/s00702-023-02686-7"},{"key":"14651_CR38","unstructured":"Burlica A. Country of the Month: Estonia - eanpages. eanpages. Published July 6, 2020. https:\/\/www.eanpages.org\/2020\/07\/06\/country-of-the-month-estonia-2\/."},{"issue":"1","key":"14651_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/jpd-230117","volume":"14","author":"JG Goldman","year":"2024","unstructured":"Goldman JG, Volpe D, Ellis TD, et al. Delivering multidisciplinary rehabilitation care in Parkinson\u2019s disease: An international consensus statement. J Parkinson\u2019s Disease. 2024;14(1):135\u201366. https:\/\/doi.org\/10.3233\/jpd-230117.","journal-title":"J Parkinson\u2019s Disease"},{"key":"14651_CR40","doi-asserted-by":"publisher","unstructured":"Weise D, Claus I, Dresel C, et al. Multidisciplinary care in Parkinson\u2019s disease. J Neural Transm. Published online July 2024;23. https:\/\/doi.org\/10.1007\/s00702-024-02807-w.","DOI":"10.1007\/s00702-024-02807-w"},{"key":"14651_CR41","unstructured":"Gemeinsamer Bundesausschuss. Patienteninformation - Genehmigung eines langfristigen \u00adHeilmittelbedarfs. www.g-ba.de. Published April 2021. https:\/\/www.g-ba.de\/downloads\/17-98-3382\/2021-04-01_G-BA_Patienteninformation_langfristiger-Heilmittelbedarf_bf.pdf."},{"key":"14651_CR42","doi-asserted-by":"publisher","unstructured":"Lars T\u00f6nges, Buhmann C, Eggers C, et al. Guideline Parkinson\u2019s disease of the German society of neurology (Deutsche Gesellschaft f\u00fcr Neurologie): concepts of care. Journal Neurology Published online July. 2024;6. https:\/\/doi.org\/10.1007\/s00415-024-12546-3.","DOI":"10.1007\/s00415-024-12546-3"},{"key":"14651_CR43","unstructured":"Paat G, Merilain M. Assessing needs of care in European Nations long-term care in ESTONIA. 2010. https:\/\/www.files.ethz.ch\/isn\/122398\/Estonia.pdf."},{"key":"14651_CR44","unstructured":"European Commission. State of Health in the EU Lithuania. Country Health Profile 2023. OECD.org. Published 2023. https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/reports\/2023\/12\/lithuania-country-health-profile-2023_7ab0a5d9\/5ed683c8-en.pdf"},{"key":"14651_CR45","unstructured":"Lietuvos \u017emoni\u0173 su negalia s\u0105junga. Paliatyviosios pagalbos paslaugos namuose - Lietuvos \u017emoni\u0173 su negalia s\u0105junga. Lietuvos \u017emoni\u0173 su negalia s\u0105junga. Published 2025. https:\/\/www.negalia.lt\/naudinga-info\/sveikata\/paliatyviosios-pagalbos-paslaugos-namuose\/."},{"key":"14651_CR46","unstructured":"Statistisches Bundesamt. Gesundheitsausgaben im EU-Vergleich 2020 - Statistisches Bundesamt. www.destatis.de. Published 2025. https:\/\/www.destatis.de\/Europa\/DE\/Thema\/Bevoelkerung-Arbeit-Soziales\/Gesundheit\/Gesundheitsausgaben.html."},{"key":"14651_CR47","unstructured":"World Health Organization. Domestic general government health expenditure (GGHE-D) as percentage of current health expenditure (CHE) (%). www.who.int. Published 2022. https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/domestic-general-government-health-expenditure-(gche-d)-as-percentage-of-current-health-expenditure"},{"key":"14651_CR48","unstructured":"World Bank Group. Out-of-pocket expenditure (% of current health expenditure) | Data. Worldbank.org. Published 2019. https:\/\/data.worldbank.org\/indicator\/SH.XPD.OOPC.CH.ZS."},{"issue":"13","key":"14651_CR49","doi-asserted-by":"publisher","first-page":"e1415","DOI":"10.1212\/wnl.0000000000009039","volume":"94","author":"EL Reynolds","year":"2020","unstructured":"Reynolds EL, Burke JF, Banerjee M, et al. Association of out-of-pocket costs on adherence to common neurologic medications. Neurology. 2020;94(13):e1415\u201326. https:\/\/doi.org\/10.1212\/wnl.0000000000009039.","journal-title":"Neurology"},{"issue":"2","key":"14651_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/mlr.0b013e3181c12e53","volume":"48","author":"M Heisler","year":"2010","unstructured":"Heisler M, Choi H, Rosen AB, et al. Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost. Med Care. 2010;48(2):87\u201394. https:\/\/doi.org\/10.1097\/mlr.0b013e3181c12e53.","journal-title":"Med Care"},{"key":"14651_CR51","doi-asserted-by":"publisher","unstructured":"Barrios-Rodr\u00edguez UR, Requena P, Mariola Borowska OJ. Enhancing therapy adherence: impact on clinical outcomes, healthcare costs, and patient quality of life. Medicina. 2025;61(1):153\u2013153. https:\/\/doi.org\/10.3390\/medicina61010153.","DOI":"10.3390\/medicina61010153"},{"key":"14651_CR52","doi-asserted-by":"crossref","unstructured":"Williams L, Qiu J, Waller S, Tsui D, Griffith J, Fung V. An approach to acute clinical deterioration in patients with late-stage Parkinson\u2019s disease. Australian J Gen Pract Published 2022. https:\/\/www1.racgp.org.au\/ajgp\/2022\/august\/acute-clinical-deterioration-in-parkinsons-disease","DOI":"10.31128\/AJGP-03-22-6363"},{"key":"14651_CR53","doi-asserted-by":"publisher","unstructured":"Schr\u00f6ter N, Sajonz BEA, Jost WH, Rijntjes M, Coenen VA, Groppa S. Advanced therapies in Parkinson\u2019s disease: an individualized approach to their indication. J Neural Transm (Vienna, Austria: 1996). Published online April 13, 2024. https:\/\/doi.org\/10.1007\/s00702-024-02773-3.","DOI":"10.1007\/s00702-024-02773-3"},{"key":"14651_CR54","unstructured":"Sullivan J. Does medicare cover deep brain stimulation? Medicalnewstoday.com. Published February 6, 2025. https:\/\/www.medicalnewstoday.com\/articles\/does-medicare-cover-deep-brain-stimulation. Accessed 26 Mar 2025."},{"issue":"2","key":"14651_CR55","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3233\/JPD-202348","volume":"11","author":"K Smilowska","year":"2021","unstructured":"Smilowska K, van Wamelen DJ, Pietrzykowski T, et al. Cost-effectiveness of device-aided therapies in Parkinson\u2019s disease: a structured review. J Parkinson\u2019s Disease. 2021;11(2):475\u201389. https:\/\/doi.org\/10.3233\/JPD-202348.","journal-title":"J Parkinson\u2019s Disease"},{"issue":"7","key":"14651_CR56","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/ner.12474","volume":"19","author":"JB Pietzsch","year":"2016","unstructured":"Pietzsch JB, Garner AM, Marks WJ. Cost-effectiveness of deep brain stimulation for advanced Parkinson\u2019s disease in the United States. Neuromodulation: J Int Neuromodulation Soc. 2016;19(7):689\u201397. https:\/\/doi.org\/10.1111\/ner.12474.","journal-title":"Neuromodulation: J Int Neuromodulation Soc"},{"key":"14651_CR57","doi-asserted-by":"crossref","unstructured":"Gray B, Sarnak D, Tanke M. ParkinsonNet: an innovative dutch approach to patient-centered care for a degenerative disease. www.commonwealthfund.org. Published Dec 23, 2016. https:\/\/www.commonwealthfund.org\/publications\/case-study\/2016\/dec\/parkinsonnet-innovative-dutch-approach-patient-centered-care.","DOI":"10.15868\/socialsector.26197"},{"key":"14651_CR58","unstructured":"Swedish. Parkinson\u2019s Foundation designates Swedish\u2019s Movement Disorders Program as a Comprehensive Care Center. Swedish.org. Published 2023. https:\/\/www.swedish.org\/news\/uf\/684045389?streamid=3129974."},{"key":"14651_CR59","doi-asserted-by":"publisher","unstructured":"Cooley Hidecker, Landers, Piccorelli, Bush, Singh. Coordinated speech therapy, physiotherapy, and pharmaceutical care telehealth for people with Parkinson disease in rural communities: an exploratory, 8-week cohort study for feasibility, safety, and signal of efficacy. Rural and Remote Health. Published online January 13, 2022. https:\/\/doi.org\/10.22605\/rrh6679.","DOI":"10.22605\/rrh6679"},{"issue":"12","key":"14651_CR60","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.3390\/brainsci12121735","volume":"12","author":"E Cubo","year":"2022","unstructured":"Cubo E, Delgado-L\u00f3pez PD. Telemedicine in the management of Parkinson\u2019s disease: achievements, challenges, and future perspectives. Brain Sci. 2022;12(12):1735. https:\/\/doi.org\/10.3390\/brainsci12121735.","journal-title":"Brain Sci"},{"issue":"2","key":"14651_CR61","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/02813430802030090","volume":"26","author":"A H\u00e5kansson","year":"2008","unstructured":"H\u00e5kansson A, Ovhed I, Jurgutis A, Kalda R, Ticmane G. Family medicine in the Baltic countries. Scand J Prim Health Care. 2008;26(2):67\u20139. https:\/\/doi.org\/10.1080\/02813430802030090.","journal-title":"Scand J Prim Health Care"},{"key":"14651_CR62","doi-asserted-by":"publisher","unstructured":"Thomas S, Edwards E, Kobylecki C. Parkinson\u2019s nurses are crucial for the management of Parkinson\u2019s disease: 2007\u20132024. J Parkinson\u2019s Dis. 2024;14(1):1\u20139. https:\/\/doi.org\/10.3233\/jpd-230224.","DOI":"10.3233\/jpd-230224"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14651-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14651-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14651-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:33:21Z","timestamp":1782718401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14651-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14651"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14651-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used only publicly available policy documents, reimbursement databases, formularies, clinical guidelines, and secondary literature. No patient-level data, human participants, biological samples, or private records were involved. Expert input was limited to non-identifiable, system-level contextual clarification. Therefore, formal ethics approval and informed consent to participate were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"873"}}